MBB Public Markets I LLC Invests $582,000 in DaVita Inc. (NYSE:DVA)

MBB Public Markets I LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 4,200 shares of the company’s stock, valued at approximately $582,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. 8 Knots Management LLC acquired a new stake in DaVita in the 4th quarter valued at approximately $89,504,000. Doma Perpetual Capital Management LLC bought a new position in shares of DaVita in the 4th quarter valued at about $53,076,000. Harvard Management Co. Inc. acquired a new stake in DaVita during the 2nd quarter worth $55,115,000. Pinebridge Investments L.P. grew its stake in shares of DaVita by 148.8% during the fourth quarter. Pinebridge Investments L.P. now owns 268,601 shares of the company’s stock worth $28,139,000 after purchasing an additional 160,630 shares during the period. Finally, Lazard Asset Management LLC increased its stake in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after acquiring an additional 153,008 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE:DVA opened at $162.75 on Wednesday. The stock has a market cap of $13.65 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The stock’s 50-day moving average is $151.04 and its 200-day moving average is $142.52. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $166.04.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same period in the prior year, the business posted $2.08 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Equities research analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current year.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 over the last ninety days. Insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DVA. Bank of America raised their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial lifted their target price on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Tuesday, August 20th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Finally, TD Cowen boosted their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.